Where it trades today
trading 4% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- IDXX trades at 36.0x earnings, well above the healthcare average of 22.0x, so the market is already pricing in above-consensus execution.
- IDXX carries a beta of 1.54, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- IDXX remains in a bearish short-term trend and sits 33.6% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- IDXX is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- This name works better as a satellite or higher-conviction growth position because it can amplify market swings in both directions.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in IDXX.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for IDXX come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for IDXX. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What IDEXX Laboratories does
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services,…
What analysts expect
IDXX carries a buy consensus from 13 analysts, with an average price target of $698.92 versus $511.65 today (+36.6%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
IDXX generated $4.55B in trailing revenue (9.7% year over year), with a 25.0% net margin, and $909.37M of free cash flow, against $899.15M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.30B | $2.66B | $1.36B | $1.06B | $13.17 | $1.04B |
| 2024 | $3.90B | $2.38B | $1.13B | $887.87M | $10.77 | $798.08M |
| 2023 | $3.66B | $2.19B | $1.10B | $845.04M | $10.17 | $772.88M |
| 2022 | $3.37B | $2.00B | $898.76M | $679.09M | $8.12 | $384.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
IDXX beside the healthcare names it is usually measured against.
What the chart is saying
IDEXX Laboratories trades at $511.65, 33.6% below its 52-week high. With a beta of 1.54, it shows more sensitivity to what the wider market does.
Questions people ask about it
Is IDXX a good buy right now?
IDEXX Laboratories trades at 36.0x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 23.5% volatility.
Does IDXX pay dividends?
IDEXX Laboratories does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is IDXX?
With 30-day annualized volatility of 23.5% and beta of 1.54, IDXX is classified as Medium risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for IDXX?
The average analyst price target for IDEXX Laboratories (IDXX) is $698.92 based on 13 analyst estimates, about 36.6% above the current price of $511.65. The published range runs from $470.00 to $805.00.
How much revenue does IDXX generate?
IDEXX Laboratories reported $4.55B in trailing twelve-month revenue. Revenue growth is running at 9.7% year over year. Net margin sits at 25.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.